

# Mary-Ellen Taplin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4015994/publications.pdf>

Version: 2024-02-01

65  
papers

6,021  
citations

293460

24  
h-index

145109

60  
g-index

69  
all docs

69  
docs citations

69  
times ranked

9663  
citing authors

#	ARTICLE	IF	CITATIONS
1	Modeling Androgen Deprivation Therapyâ€‘Induced Prostate Cancer Dormancy and Its Clinical Implications. <i>Molecular Cancer Research</i> , 2022, 20, 782-793.	1.5	10
2	Implementation of a prostate cancerâ€‘specific targeted sequencing panel for credentialing of patientâ€‘derived cell lines and genomic characterization of patient samples. <i>Prostate</i> , 2022, , .	1.2	1
3	Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis. <i>Clinical Cancer Research</i> , 2022, 28, 928-938.	3.2	29
4	PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients (pts) with localized or locally advanced high-risk prostate cancer (PC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS285-TPS285.	0.8	3
5	PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS191-TPS191.	0.8	1
6	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 6-11.	0.9	4
7	Genetic testing in prostate cancer management: Considerations informing primary care. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 360-371.	157.7	15
8	A phase Ia/Ib study of talazoparib in combination with tazemetostat in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS195-TPS195.	0.8	1
9	The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial. <i>Clinical Cancer Research</i> , 2022, 28, 860-869.	3.2	4
10	A phase Ia/Ib study of talazoparib in combination with tazemetostat in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS5098-TPS5098.	0.8	0
11	Overall survival (OS) and biomarker results from combat: A phase 2 study of bipolar androgen therapy (BAT) plus nivolumab for patients with metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 5064-5064.	0.8	3
12	The Impact of COVID-19 on Clinical Trial Execution at the Dana-Farber Cancer Institute. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1453-1459.	3.0	39
13	Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2011-2022.	3.2	19
14	Transcriptional mediators of treatment resistance in lethal prostate cancer. <i>Nature Medicine</i> , 2021, 27, 426-433.	15.2	90
15	COMBAT-CRPC: Concurrent administration of bipolar androgen therapy (BAT) and nivolumab in men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 5014-5014.	0.8	9
16	Differential responses to taxanes and PARP inhibitors (PARPi) in <i>ATM-</i> versus <i>BRCA2-</i> mutated metastatic castrate-resistant prostate cancer (mCRPC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2021, 39, 5040-5040.	0.8	0
17	Identification and management of pathogenic mutations in BRCA1, BRCA2, and PALB2 in a tumor-only genomic testing program.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10528-10528.	0.8	1
18	A phase 2 study of berzosertib (M6620) in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5034-5034.	0.8	4

#	ARTICLE	IF	CITATIONS
19	Enzalutamide With Radiation Therapy for Intermediate-Risk Prostate Cancer: A Phase 2 Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1416-1422.	0.4	6
20	Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer. <i>Cell Reports</i> , 2021, 36, 109665.	2.9	24
21	Multiparametric MRI as a Biomarker of Response to Neoadjuvant Therapy for Localized Prostate Cancer—A Pilot Study. <i>Academic Radiology</i> , 2020, 27, 1432-1439.	1.3	9
22	Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. <i>JCO Oncology Practice</i> , 2020, 16, 811-819.	1.4	35
23	Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. <i>Clinical Cancer Research</i> , 2020, 26, 6122-6131.	3.2	9
24	A randomized controlled trial of video-education or in-person genetic counseling for men with prostate cancer (ProGen).. <i>Journal of Clinical Oncology</i> , 2020, 38, 1507-1507.	0.8	7
25	Androgen Receptor Modulation Optimized for Response—Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 76, 843-851.	0.9	36
26	Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 275-282.e1.	0.9	42
27	Genomic correlates of clinical outcome in advanced prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 11428-11436.	3.3	839
28	A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2019, 125, 524-532.	2.0	8
29	Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 420-427.	2.0	49
30	Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 5008-5008.	0.8	31
31	CALGB 90203 (Alliance): Radical prostatectomy (RP) with or without neoadjuvant chemohormonal therapy (CHT) in men with clinically localized, high-risk prostate cancer (CLHRPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 5079-5079.	0.8	9
32	ProSTAR: A phase Ib/II study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS335-TPS335.	0.8	7
33	Genetic counseling processes and outcomes among prostate cancer patients (ProGen).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS343-TPS343.	0.8	1
34	Metacure: Multi-arm multimodality therapy for very high risk localized and low volume metastatic prostatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS349-TPS349.	0.8	3
35	Association of serum androgen and drug levels with response to abiraterone.. <i>Journal of Clinical Oncology</i> , 2019, 37, 208-208.	0.8	0
36	PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS5100-TPS5100.	0.8	6

#	ARTICLE	IF	CITATIONS
37	Evaluating a Video-Based, Personalized Webpage in Genitourinary Oncology Clinical Trials: A Phase 2 Randomized Trial. <i>Journal of Medical Internet Research</i> , 2019, 21, e12044.	2.1	2
38	Clinical and Genomic Characterization of Low-Grade Prostate-specific Antigen, High-grade Prostate Cancer. <i>European Urology</i> , 2018, 74, 146-154.	0.9	72
39	Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 364-372.	2.0	48
40	Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). <i>Prostate</i> , 2018, 78, 889-895.	1.2	111
41	The long tail of oncogenic drivers in prostate cancer. <i>Nature Genetics</i> , 2018, 50, 645-651.	9.4	601
42	Effects of Androgen Deprivation Therapy on Pain Perception, Quality of Life, and Depression in Men With Prostate Cancer. <i>Journal of Pain and Symptom Management</i> , 2018, 55, 307-317.e1.	0.6	26
43	Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 363-371.	1.8	27
44	Prostate Cancer-Specific Mortality Across Gleason Scores in Black vs Nonblack Men. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2479.	3.8	103
45	Mechanisms responsible for reduced erythropoiesis during androgen deprivation therapy in men with prostate cancer. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2018, 315, E1185-E1193.	1.8	24
46	Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer. <i>Journal of the Endocrine Society</i> , 2018, 2, 485-496.	0.1	33
47	Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. <i>Cell</i> , 2018, 174, 433-447.e19.	13.5	258
48	Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. <i>Cancer Research</i> , 2018, 78, 4716-4730.	0.4	56
49	Efficacy of Therapies After Galeterone in Patients With Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 463-471.	0.9	12
50	Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide. <i>Clinical Cancer Research</i> , 2017, 23, 6812-6822.	3.2	77
51	Testicular vs adrenal sources of hydroxy-androgens in prostate cancer. <i>Endocrine-Related Cancer</i> , 2017, 24, 393-404.	1.6	10
52	Prostate cancer: Developing novel approaches to castration-sensitive disease. <i>Cancer</i> , 2017, 123, 29-42.	2.0	8
53	Radium-223 Use in Clinical Practice and Variables Associated With Completion of Therapy. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e289-e298.	0.9	40
54	Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer. <i>ELife</i> , 2017, 6, .	2.8	83

#	ARTICLE	IF	CITATIONS
55	Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e299-e305.	0.9	11
56	Genetic Effect of Chemotherapy Exposure in Children of Testicular Cancer Survivors. <i>Clinical Cancer Research</i> , 2016, 22, 2183-2189.	3.2	15
57	Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer. <i>Cancer</i> , 2015, 121, 2603-2611.	2.0	9
58	Integrative Clinical Genomics of Advanced Prostate Cancer. <i>Cell</i> , 2015, 161, 1215-1228.	13.5	2,660
59	Has the Time Arrived for Biomarker-Directed Therapy in Castration-Resistant Prostate Cancer?. <i>JAMA Oncology</i> , 2015, 1, 577.	3.4	5
60	Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors. <i>PLoS ONE</i> , 2015, 10, e0124711.	1.1	16
61	Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Prostate Cancer Clinical Trials: Potential Roles and Possible Pitfalls. <i>Translational Oncology</i> , 2014, 7, 120-129.	1.7	20
62	Secondary hormone therapy for castration-resistant prostate cancer. <i>Oncology</i> , 2013, 27, 371-2.	0.4	0
63	Androgen receptor: role and novel therapeutic prospects in prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1495-1508.	1.1	58
64	Drug Insight: role of the androgen receptor in the development and progression of prostate cancer. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 236-244.	4.3	185
65	Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. <i>Urology</i> , 2005, 66, 386-391.	0.5	89